WESTMINSTER, CO--(Marketwired - March 19, 2014) -
ARCA biopharma, Inc. (NASDAQ: ABIO
), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Michael R. Bristow, president and CEO, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network Show. Any interested parties may tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
The live interview details are as follows:
Date: Wednesday, March 19, 2014
Start Time: 11:05am PDT | 12:05pm MDT | 2:05pm EDT (U.S.)
Network: Clear Channel
Station: DFW 1190AM KFXR
Show: The Traders Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate, Gencaro™ (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit www.arcabiopharma.com.
About Clear Channel: Clear Channel's Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.
About Michael Yorba: Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has produced and hosted The Traders Network Show broadcasted live daily on Clear Channel DFW 1190AM KFXR from 1pm - 3pm CT, Monday-Friday.
Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It's a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more... shift your thinking and join us as we deliver "tomorrow's ideas today" on Clear Channel's The Traders Network Show.
A www.1800PublicRelations.com PR Event
Safe Harbor Statement
This press release and the anticipated interview contain "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company's capital to support its operations, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro's potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company's intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA's filings with the SEC, including without limitation the Company's annual report on Form 10-K for the year ended December 31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.